Evotec partner Bayer today reported more detailed results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of eliapixant in patients with refractory chronic cough (“RCC”). Eliapixant (BAY1817080) is an investigational orally administered, potent and selective P2X3 receptor antagonist derived from a former multi-target research collaboration between Bayer and Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-bayer-phase-iib-trial-shows-eliapixant-significantly-decreases-cough-frequency-in-patients-with-refractory-chronic-cough-6096